Subscribe
amelia19-shutterstock-com
Amelia19 / Shutterstock.com
4 June 2015EuropePaul England and Anja Lunze

UPC: The true meaning of opt-out

Our previous article discussed which type of patent can be litigated where in the new Unified Patent Court (UPC) system. This included the dual track—national and UPC—jurisdiction for classical European patents that will operate during the transitional period.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Patent firms unveil joint UPC ‘powerhouse’
15 November 2022   Firms aim to form a UPC litigation alliance | New court has significant implications for life sciences | UPC faces calls for delay over concerns regarding its case management system.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Big Pharma
Patent firms unveil joint UPC ‘powerhouse’
15 November 2022   Firms aim to form a UPC litigation alliance | New court has significant implications for life sciences | UPC faces calls for delay over concerns regarding its case management system.

More on this story

Big Pharma
Patent firms unveil joint UPC ‘powerhouse’
15 November 2022   Firms aim to form a UPC litigation alliance | New court has significant implications for life sciences | UPC faces calls for delay over concerns regarding its case management system.

More features

Herbert Smith Freehills and Kramer Levin in $2bn merger talks
CRISPR patents revoked following Nobel Prize winners’ withdrawal
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Cooley adds ex-Gowling partner
How post-filing data rescued Novo Nordisk’s Ozempic patent in China